4.7 Review

Antiphospholipid syndrome and kidney disease

期刊

KIDNEY INTERNATIONAL
卷 91, 期 1, 页码 34-44

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2016.06.026

关键词

antiphospholipid antibodies; mTORC pathway; vasculopathy

资金

  1. Emmanuel Boussard Foundation (London, UK)
  2. Day Solvay Foundation (Paris, France)
  3. INSERM
  4. Assistance Publique-Hopitaux de Paris
  5. Universite Paris Descartes

向作者/读者索取更多资源

The antiphospholipid syndrome is a common autoimmune disease caused by pathogenic antiphospholipid antibodies, leading to recurrent thrombosis and/or obstetrical complications. Importantly for nephrologists, antiphospholipid antibodies are associated with various renal manifestations including large renal vessel thrombosis, renal artery stenosis, and a constellation of intrarenal lesions that has been termed antiphospholipid nephropathy. This last condition associates various degrees of acute thrombotic microangiopathy, proliferative and fibrotic lesions of the intrarenal vessels, and ischemic modifications of the renal parenchyma. The course of the disease can range from indolent nephropathy to devastating acute renal failure. The pejorative impact of antiphospholipid antibody related renal complication is well established in the context of systemic lupus erythematous or after renal transplantation. In contrast, the exact significance of isolated antiphospholipid nephropathy remains uncertain. The evidence to guide management of the renal complications of antiphospholipid syndrome is limited. However, the recent recognition of the heterogeneous molecular mechanisms underlying the progression of intrarenal vascular lesions in antiphospholipid syndrome have opened promising tracks for patient monitoring and targeted therapeutic intervention.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据